[Edaily Reporter KIM SAE-MI ] Medical AI company Coreline Soft Co., Ltd.(384470)has secured a long-term reference based on 10 years of technical and operational support by entering Canon’s local image interpretation network in conjunction with the implementation of Germany’s lung cancer screening program.

Bid for Rostau via Canon… First Entry into German Lung Cancer Screening Workflow

According to the medical AI industry on the 7th, Coreline Soft Co., Ltd. secured a contract to supply solutions for lung cancer screening in the Rostau region of Germany through Canon Medical Systems GmbH (hereinafter “Canon”). Coreline Soft Co., Ltd.’s chest computed tomography (CT) AI solution was adopted as part of Canon’s participation in the Rostau regional tender.

This contract is structured to provide initial software supply, installation, and implementation, followed by 10 years of technical and operational support. It is not a one-year usage contract or a fixed-term license that expires after 10 years, but rather a combination of initial system implementation and long-term technical support.

The solution will be supplied to a secondary reading network linked to multiple primary reading sites within the German state of Saxony-Anhalt. Coreline Soft Co., Ltd.’s solution will be utilized primarily for LDCT-based lung cancer screening and is scheduled for use within the local clinical environment. It will be applied to connect images captured at various medical institutions with specialized reading centers and to systematically manage AI analysis results and reading information.

Starting in April of this year, Germany incorporated low-dose computed tomography (LDCT) lung cancer screening for high-risk smokers and former smokers into its statutory health insurance system. As early lung cancer screening enters the mainstream in Germany—one of Europe’s largest healthcare markets—demand for the establishment of screening infrastructure that connects CT equipment, interpretation software, and specialized medical personnel is gaining momentum.

According to the company, Germany’s lung cancer screening program operates as an integrated workflow—from participant selection to low-dose CT scans, primary and secondary image interpretation, follow-up management, and quality control—and demand for AI-based screening infrastructure to support this is expanding.

Supply of the ‘AVIEW’ Platform Covering the Entire Screening Process

The scope of this supply includes Coreline Soft Co., Ltd.’s “AVIEW LCS Plus,” “AVIEW COPD,” and “AVIEW HUB.”

AVIEW LCS Plus detects pulmonary nodules in low-dose chest CT scans and measures their size and volume. It analyzes nodule growth rates and volume doubling times by comparing them with past images, and also calculates information related to emphysema and coronary artery calcification based on non-contrast CT scans. It supports the lung cancer screening process by enabling the simultaneous assessment of not only pulmonary nodules but also information on comorbid pulmonary diseases and cardiovascular disease risk.

AVIEW COPD automatically segments the lungs, lung lobes, and airways, and provides quantitative indicators related to chronic obstructive pulmonary disease (COPD)—such as emphysema and air trapping—based on inspiratory and expiratory CT scans.

AVIEW HUB serves to integrate AI analysis results into actual screening operations. It links images and analysis results between primary and secondary reading institutions and provides integrated management of examination lists and reading tasks across multiple institutions. It also offers features necessary for multi-center lung cancer screening, such as sharing and joint evaluation of reading results, pseudonymization of patient information, follow-up management, and quality control.

Coreline Soft Co., Ltd. highlights its integrated workflow capabilities—which support AI analysis, interpretation coordination, and follow-up management—as a key differentiator in the German market, setting it apart from software that merely detects lung nodules. The company also cites its experience in multi-center screening, gained through the “HANSE” lung cancer screening study conducted in Germany, as a competitive advantage.

HANSE has been conducted since 2021 at certified lung cancer centers in northern Germany—including Hanover, Lübeck, and Großhansdorf—involving more than 5,000 participants. Coreline Soft Co., Ltd.’s AVIEW was utilized in this study for lung nodule detection, volume measurement, growth rate analysis, and dual-reading support. The company maintains that, based on this, it has gained operational experience that enables it to adapt to Germany’s actual screening environment and interpretation procedures.

New Contracts in Germany on the Rise… Will This Serve as a Springboard for Expansion in the European Lung Cancer Screening Market

?
The company’s local operations in Germany are also expanding rapidly. Following the signing of 10 new hospital contracts in Germany last year, Coreline Soft Co., Ltd. secured an additional 11 contracts in the first quarter of this year, 12 in April, and 21 in May. The cumulative number of new contracts from January to May this year exceeded 44, surpassing 4.4 times the total number of contracts signed in all of last year. The company expects the cumulative number of new contracts for the first half of the year, including those signed in June, to reach approximately 60.

Building on its track record with major German medical institutions—including Charité, Bonn University Hospital, Heidelberg University Hospital, and Hannover Medical School—Coreline Soft Co., Ltd. is expanding its network of partnerships with local hospitals for image interpretation. As Germany’s lung cancer screening program expands sequentially based on state-by-state approvals and the establishment of primary and secondary interpretation networks, the number of operational sites and the volume of screenings are expected to become key indicators of business growth.

A Coreline Soft Co., Ltd. official stated, “This supply marks a case where Canon’s medical imaging infrastructure and Coreline Soft Co., Ltd.’s AI analysis and interpretation integration technology are being applied together to local screening workflows in conjunction with the implementation of Germany’s lung cancer screening program,” adding, “Based on our experience ranging from initial deployment to long-term technical and operational support, we will expand our operational AI infrastructure in the European lung cancer screening market.”